Bharath Bio Tech’s Covaxin and Serum Institute and AstraZeneca’s Covishield may compete in the race of vaccine as Covaxin is also ready to enter the market.  Yesterday, the expert panel of India’s drug regulator recommended granting permission for restricted emergency use of the indigenously developed Covid-19 vaccine ‘Covaxin’ in “public interest as an abundant precaution.” Covishiled also got permission from the Drugs authority a day before.

Leave a Reply

Your email address will not be published.